Compare · BIOX vs EVGN
BIOX vs EVGN
Side-by-side comparison of Bioceres Crop Solutions Corp. (BIOX) and Evogene Ltd (EVGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIOX and EVGN operate in Agricultural Chemicals (Industrials), so they compete in similar markets.
- BIOX is the larger of the two at $502.3M, about 57.8x EVGN ($8.7M).
- EVGN has been more active in the news (8 items in the past 4 weeks vs 3 for BIOX).
- BIOX has more recent analyst coverage (7 ratings vs 4 for EVGN).
- Company
- Bioceres Crop Solutions Corp.
- Evogene Ltd
- Price
- $0.43+6.27%
- $0.54-0.20%
- Market cap
- $502.3M
- $8.7M
- 1M return
- -
- +0.61%
- 1Y return
- -
- -57.11%
- Industry
- Agricultural Chemicals
- Agricultural Chemicals
- Exchange
- AMEX
- NASDAQ
- IPO
- News (4w)
- 3
- 8
- Recent ratings
- 7
- 4
Bioceres Crop Solutions Corp.
Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. The company operates through three segments: Seed and Integrated Products, Crop Protection, and Crop Nutrition. The Seed and Integrated Products segment develops and commercializes seed technology, biotechnological events, germplasm, and seed treatments. The Crop Protection segment develops, produces, and markets adjuvants, insecticides, fungicides, and baits. The Crop Nutrition segment develops, produces, commercializes, and sells inoculants, bio-inductors, and biological and microgranulated fertilizers. In addition, the company offers HB4, a drought tolerant seed technology program. It operates in Argentina, Austria, Bolivia, Brazil, Lebanon, the United States, Italy, Paraguay, the United Kingdom, South Africa, France, Canada, Ukraine, Uruguay, and internationally. The company is headquartered in Rosario, Argentina. Bioceres Crop Solutions Corp. is a subsidiary of Bioceres LLC.
Evogene Ltd
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd., a subsidiary of Tikun Olam-Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
Latest BIOX
- Amendment: CEO Trucco Federico gifted 130,000 units of Ordinary Shares (SEC Form 4)
- CEO Trucco Federico gifted 150,000 units of Ordinary Shares (SEC Form 4)
- SEC Form 4 filed by CFO Simmermacher Ezequiel
- SEC Form 6-K filed by Bioceres Crop Solutions Corp.
- SEC Form 6-K filed by Bioceres Crop Solutions Corp.
- SEC Form 3 filed by new insider Duraiswami Narain
- SEC Form 6-K filed by Bioceres Crop Solutions Corp.
- Amendment: SEC Form 3 filed by new insider Simmermacher Ezequiel
- New insider Mago Yogesh claimed ownership of 55,399 units of Ordinary Shares (SEC Form 3)
- Bioceres Crop Solutions Reports Fiscal Third Quarter 2026 Financial and Operational Results
Latest EVGN
- Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees
- Evogene Reports Second Quarter and First Half 2026 Financial Results
- SEC Form 6-K filed by Evogene Ltd
- Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation
- Amendment: SEC Form SCHEDULE 13D/A filed by Evogene Ltd
- Director Recanati Leon bought $292,100 worth of Ordinary Shares (460,000 units at $0.64), increasing direct ownership by 52% to 1,343,886 units (SEC Form 4)
- SEC Form SCHEDULE 13D filed by Evogene Ltd
- Director Recanati Leon bought $400,000 worth of Ordinary Shares (800,000 units at $0.50), increasing direct ownership by 954% to 883,886 units (SEC Form 4)
- SEC Form 6-K filed by Evogene Ltd
- Evogene Schedules Second Quarter 2026 Financial Results Release